TG Therapeutics heads into its June 11 earnings call in a starkly different place than it was a week ago — the stock has ripped 18% higher to $43.37 while a large short position remains firmly in place, setting up a direct confrontation between momentum buyers and a stubborn bear camp.
The rally has been sharp enough to matter. TGTX gained nearly 6% in Tuesday's session alone, recovering well past the $36.64 level documented in the previous note just days ago. Yet short interest has barely flinched in response — it remains at 19.2% of the free float, holding close to the rebuilt levels bears established through late May and early June. That combination of a fast-moving stock and an unmoved short base is the defining tension heading into the print. The lending market remains relaxed: availability is running at roughly 300% of short interest, and the cost to borrow has drifted lower to 0.40% — conditions that make it easy for bears to stay put or add rather than face forced covering pressure.
Options traders are not reading this as a defensive moment. The put/call ratio is near its lowest level in a year at 0.40, well below its 20-day average of 0.42, and the z-score is slightly negative — meaning calls are dominant and options positioning is more bullish than usual for this stock. That diverges sharply from the elevated short interest. Bears are concentrated in the stock loan market; the options market is leaning the other way.
The analyst community frames the disagreement clearly. Bulls, led by HC Wainwright's $70 target — raised to that level after the prior earnings print in May — point to BRIUMVI's single-infusion convenience, real-world market share gains, and a discounted cash flow case that extends well into the 2030s. JP Morgan holds an Overweight with a $46 target, close to current levels after a February trim from $49. Goldman Sachs sits at Neutral with a $39 target, below where the stock is now trading — a reminder that not everyone is a believer at these prices. Bears focus on the cost pressure side: rising R&D spend for a subcutaneous formulation, ongoing clinical expansion, and a Q1 EPS trajectory that was already declining. The ORTEX EPS momentum scores are high — 92nd percentile on the 30-day measure — but the EPS surprise rank is just 17th percentile, meaning the company has not been a consistent beat-and-raise story.
Past earnings reactions add context without guiding a prediction. The May 2026 print produced a 19% one-day gain and held most of that over five sessions. The prior event, in early February, delivered a more modest 6.6% initial move before extending to 27% over the following week. Both were positive surprises. The question tomorrow is whether BRIUMVI's commercial momentum and any update on the subcutaneous program justify the stock's renewed push toward the mid-$40s — and whether a short base of nearly 19% of the float, sitting on positions rebuilt just weeks ago, will be tested by what the company reports.
See the live data behind this article on ORTEX.
Open TGTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
